2017
Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making
Dzimitrowicz H, Mougalian S, Storms S, Hurd S, Chagpar AB, Killelea BK, Horowitz NR, Lannin DR, Harigopal M, Hofstatter E, DiGiovanna MP, Adelson KB, Silber A, Abu-Khalaf M, Chung G, Zaheer W, Abdelghany O, Hatzis C, Pusztai L, Sanft TB. Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making. JCO Oncology Practice 2017, 13: jop.2017.022731. PMID: 29048991, DOI: 10.1200/jop.2017.022731.Peer-Reviewed Original ResearchConceptsAdjuvant therapy decisionsRecurrence scoreChemotherapy useRS testingMedical oncologistsHistorical controlsChemotherapy decisionsTherapy decisionsEligibility criteriaNational Comprehensive Cancer Network guidelinesProspective quality improvement projectEarly-stage breast cancerAdjuvant chemotherapy recommendationsTime of diagnosisTime of surgeryQuality improvement projectTesting groupChemotherapy initiationChemotherapy recommendationsMedian timeTrial enrollmentNetwork guidelinesSurgical oncologistsClinical trialsBreast cancer
2009
Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2.
Misra D, Adelson K, Halpern M, Jaffer S, Nagi C, Bleiweiss I, Mandeli J, Raptis G, Germain D. Correlation of Oncotype DX Recurrence Score with Cyclin D1 and ErbB2. Cancer Research 2009, 69: 3035-3035. DOI: 10.1158/0008-5472.sabcs-09-3035.Peer-Reviewed Original ResearchNode-negative breast cancerOncotype DX recurrence scoreOncotype DXRecurrence scoreDX recurrence scoreNegative breast cancerBreast cancerTamoxifen resistanceCyclin D1 overexpressionCyclin D1Cyclin D1 expressionFree survivalOverall survivalEarly-stage node-negative breast cancerColorectal Cancer Study GroupLower relapse-free survivalTamoxifen-resistant breast cancerD1 expressionAdjuvant tamoxifen therapyCancer Study GroupProgression-free survivalUse of chemotherapyResistant breast cancerHigh cyclin D1 expressionHigh recurrence score